William Blair & Company
AQST icon

William Blair & Company’s Aquestive Therapeutics AQST Stock Holding History

William Blair & Company’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.4K Buy
+14,565
New +$59.1K ﹤0.01% 1670

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

William Blair & Company's AQST Position: Q1 2026 in Review

William Blair & Company opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 14,565 shares worth $60.4K. The stake represents ﹤0.01% of the portfolio and ranks #1670 among its holdings.

179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • William Blair & Company held 14,565 shares of Aquestive Therapeutics worth $60.4K as of Q1 2026.
  • Aquestive Therapeutics was a new William Blair & Company position in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1670 holding.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.